Keywords: novartis, tavist, gains, otc, approval, consumer, health
Novartis' Tavist gains US OTC approval
Article | 13 March 2001
Novartis Consumer Health has received US Food and Drug Administrationapproval for Tavist Allergy/Sinus/ Headache for marketing over-the-counter. The company ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Pfizer to split-off remaining 80% interest in Zoetis
